To our knowledge, this study is the first to assess pre-diagnostic SDC1 and SDC4 levels and breast cancer risk, offering novel insights into the knowledge of pre-diagnostic levels of SDC4 as a potential pathogenesis factor and as a potential biomarker of inflammation-associated processes in breast cancer development. Here, SDC4 is linked to breast cancer.